miR-32 promotes MYC-driven prostate cancer.

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Androgen receptor (AR)-regulated microRNA-32 (miR-32) expression increases in castration-resistant prostate cancer (PC).
• Previous studies showed miR-32 overexpression potentiates prostate epithelium proliferation in transgenic mice.
• The role of elevated miR-32 in prostate adenocarcinoma growth and phenotype in vivo requires further investigation.

Purpose of the Study:

• To determine if increased miR-32 expression influences prostate adenocarcinoma growth and phenotype in vivo.
• To investigate the molecular mechanisms underlying miR-32's role in prostate cancer progression.
• To identify novel therapeutic targets associated with miR-32 activity in prostate cancer.

Main Methods:

• Utilized transgenic mice (hiMYC mice) engineered to express the MYC oncogene for prostate tumorigenesis.
• Overexpressed miR-32 in hiMYC mice to assess its impact on tumor burden and phenotype.
• Conducted gene expression analysis, immunohistochemistry (Ki-67), and assessed mitotic index and nuclear density.

Main Results:

• Overexpression of miR-32 significantly increased tumor burden and promoted a more aggressive tumor phenotype in hiMYC mice.
• Elevated miR-32 correlated with increased proliferation, nuclear density, and mitotic index.
• Identified PDK4 as a novel tumor-associated miR-32 target; human PC data showed inverse correlation between PDK4 and miR-32/Gleason score, with low PDK4 linked to recurrence.

Conclusions:

• miR-32 promotes MYC-induced prostate adenocarcinoma development and progression.
• miR-32 regulates prostate cancer secretome and impacts tumor cell metabolism via targets like PDK4.
• PDK4 is a clinically relevant metabolic target of miR-32, suggesting potential for therapeutic intervention in prostate cancer.